Immunotherapy Drug Improves Survival for Lung Cancer Patients

A bispecific antibody immunotherapy, ivonescimab, has shown to prolong the lives of individuals with newly diagnosed advanced non-small cell lung cancer. Trial results indicated a one-third reduction in the risk of death compared to chemotherapy. These findings, presented at a major oncology conference, are significant for this class of drugs and have implications for future global studies.